Difference in miRNA Expression in Functioning and Silent Corticotroph Pituitary Adenomas Indicates the Role of miRNA in the Regulation of Corticosteroid Receptors
- PMID: 35270010
- PMCID: PMC8911444
- DOI: 10.3390/ijms23052867
Difference in miRNA Expression in Functioning and Silent Corticotroph Pituitary Adenomas Indicates the Role of miRNA in the Regulation of Corticosteroid Receptors
Abstract
Corticotroph pituitary adenomas commonly cause Cushing's disease (CD), but some of them are clinically silent. The reason why they do not cause endocrinological symptoms remains unclear. We used data from small RNA sequencing in adenomas causing CD (n = 28) and silent ones (n = 20) to explore the role of miRNA in hormone secretion and clinical status of the tumors. By comparing miRNA profiles, we identified 19 miRNAs differentially expressed in clinically functioning and silent corticotroph adenomas. The analysis of their putative target genes indicates a role of miRNAs in regulation of the corticosteroid receptors expression. Adenomas causing CD have higher expression of hsa-miR-124-3p and hsa-miR-135-5p and lower expression of their target genes NR3C1 and NR3C2. The role of hsa-miR-124-3p in the regulation of NR3C1 was further validated in vitro using AtT-20/D16v-F2 cells. The cells transfected with miR-124-3p mimics showed lower levels of glucocorticoid receptor expression than control cells while the interaction between miR-124-3p and NR3C1 3' UTR was confirmed using luciferase reporter assay. The results indicate a relatively small difference in miRNA expression between clinically functioning and silent corticotroph pituitary adenomas. High expression of hsa-miR-124-3p in adenomas causing CD plays a role in the regulation of glucocorticoid receptor level and probably in reducing the effect of negative feedback mediated by corticosteroids.
Keywords: Cushing’s disease; NR3C1; glucocorticoid receptor; hsa-miR-124-3p; miRNA; neuroendocrine pituitary tumors; silent corticotroph adenoma.
Conflict of interest statement
The authors declare no conflict of interest.
Figures




Similar articles
-
The expression of glucocorticoid and mineralocorticoid receptors in pituitary tumors causing Cushing's disease and silent corticotroph tumors.Front Endocrinol (Lausanne). 2023 Mar 29;14:1124646. doi: 10.3389/fendo.2023.1124646. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37065760 Free PMC article.
-
The Role of Glucocorticoid Receptor in the Pathophysiology of Pituitary Corticotroph Adenomas.Int J Mol Sci. 2022 Jun 9;23(12):6469. doi: 10.3390/ijms23126469. Int J Mol Sci. 2022. PMID: 35742910 Free PMC article. Review.
-
Lineage-dependent role of miR-410-3p as oncomiR in gonadotroph and corticotroph pituitary adenomas or tumor suppressor miR in somatotroph adenomas via MAPK, PTEN/AKT, and STAT3 signaling pathways.Endocrine. 2019 Sep;65(3):646-655. doi: 10.1007/s12020-019-01960-7. Epub 2019 Jun 4. Endocrine. 2019. PMID: 31165412 Free PMC article.
-
Case Report: Micro-RNAs in Plasma From Bilateral Inferior Petrosal Sinus Sampling and Peripheral Blood From Corticotroph Pituitary Neuroendocrine Tumors.Front Endocrinol (Lausanne). 2022 Apr 22;13:748152. doi: 10.3389/fendo.2022.748152. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35528014 Free PMC article.
-
Pathophysiology and treatment of subclinical Cushing's disease and pituitary silent corticotroph adenomas [Review].Endocr J. 2014;61(10):941-8. doi: 10.1507/endocrj.ej14-0120. Epub 2014 Jun 29. Endocr J. 2014. PMID: 24974880 Review.
Cited by
-
Emerging Roles of miRNA, lncRNA, circRNA, and Their Cross-Talk in Pituitary Adenoma.Cells. 2022 Sep 19;11(18):2920. doi: 10.3390/cells11182920. Cells. 2022. PMID: 36139495 Free PMC article. Review.
-
The expression of glucocorticoid and mineralocorticoid receptors in pituitary tumors causing Cushing's disease and silent corticotroph tumors.Front Endocrinol (Lausanne). 2023 Mar 29;14:1124646. doi: 10.3389/fendo.2023.1124646. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37065760 Free PMC article.
-
Approaches based on natural products and miRNAs in pituitary adenomas: unveiling therapeutic intervention.Naunyn Schmiedebergs Arch Pharmacol. 2025 Jan;398(1):69-88. doi: 10.1007/s00210-024-03347-6. Epub 2024 Aug 5. Naunyn Schmiedebergs Arch Pharmacol. 2025. PMID: 39102032 Review.
-
The Role of Glucocorticoid Receptor in the Pathophysiology of Pituitary Corticotroph Adenomas.Int J Mol Sci. 2022 Jun 9;23(12):6469. doi: 10.3390/ijms23126469. Int J Mol Sci. 2022. PMID: 35742910 Free PMC article. Review.
-
Recent advances in understanding and managing pituitary adenomas.Fac Rev. 2023 Mar 21;12:6. doi: 10.12703/r/12-6. eCollection 2023. Fac Rev. 2023. PMID: 36968144 Free PMC article. Review.
References
-
- Osamura R.Y., Grossman A., Korbonits M., Kovacs K., Lopes M.B.S., Matsuno A., Trouillas J. In: WHO Classification of Tumours of Endocrine Organs. 4th ed. Lloyd R.V., Osamura R.Y., Rosari J., editors. IARC Press; Lyon, France: 2017.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Miscellaneous